Sign up for ALS Link:



https://bit.ly/3CqGbhb

Thank you for joining the webinar!

We are admitting audience members from the waiting room

Please allow a few moments for the webinar to begin



HEALEY ALS Platform Trial

Community Q&A – September 25, 2025







Healey & AMG Center

Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital





















































The HEALEY ALS Platform Trial design reduces the number of participants on placebo by sharing placebo data across multiple regimens



Thank You







Platform trials are a unique opportunity to advance science



DNA – whole genome sequencing



Neurofilaments – for all regimens



Biomarkers (Blood, CSF) – several drug-specific biomarkers




Speech Analysis – emerging digital biomarker



Home Spirometry – critical during the pandemic

Additional biomarkers/outcome measures for upcoming regimens (new patient-reported outcomes; PBMCs for stem cell generation)

Broadening the impact of placebo data from Regimens A - E



Patient Navigation Central resource for people living with ALS



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: <u>healeyalsplatform@mgh.harvard.edu</u>

Register for webinars:



https://bit.ly/3r6Nd2L

Thank you to our Patient Advisory Committee members, and to everyone who has partnered with us in research.

This progress would not be possible without you!



Upcoming Webinars (Thurs, 5:00- 5:30pm EST):

October 23 – Decoding Platform Trial Publications with Dr. Lori Chibnik